PL2205244T3 - Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych - Google Patents

Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych

Info

Publication number
PL2205244T3
PL2205244T3 PL08847113T PL08847113T PL2205244T3 PL 2205244 T3 PL2205244 T3 PL 2205244T3 PL 08847113 T PL08847113 T PL 08847113T PL 08847113 T PL08847113 T PL 08847113T PL 2205244 T3 PL2205244 T3 PL 2205244T3
Authority
PL
Poland
Prior art keywords
benzothiazol
isoxazol
morpholin
imidazo
ethoxy
Prior art date
Application number
PL08847113T
Other languages
English (en)
Inventor
Joyce K James
Shawn R Eichelberger
Traci L Savall
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of PL2205244T3 publication Critical patent/PL2205244T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL08847113T 2007-11-08 2008-11-07 Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych PL2205244T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US580307P 2007-12-07 2007-12-07
US9867608P 2008-09-19 2008-09-19
US11206008P 2008-11-06 2008-11-06
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
EP08847113.1A EP2205244B1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease

Publications (1)

Publication Number Publication Date
PL2205244T3 true PL2205244T3 (pl) 2014-01-31

Family

ID=40262072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08847113T PL2205244T3 (pl) 2007-11-08 2008-11-07 Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych

Country Status (18)

Country Link
US (1) US7968543B2 (pl)
EP (2) EP2596795A1 (pl)
JP (2) JP5645667B2 (pl)
KR (2) KR101578481B1 (pl)
CN (1) CN101835472A (pl)
AR (1) AR069244A1 (pl)
AU (1) AU2008325141B2 (pl)
CA (1) CA2696807C (pl)
CY (1) CY1114853T1 (pl)
DK (1) DK2205244T3 (pl)
ES (1) ES2436266T3 (pl)
HR (1) HRP20131083T1 (pl)
MX (1) MX2010002396A (pl)
PL (1) PL2205244T3 (pl)
PT (1) PT2205244E (pl)
SI (1) SI2205244T1 (pl)
TW (1) TW200924756A (pl)
WO (1) WO2009061446A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4610668B2 (ja) * 2006-03-17 2011-01-12 アムビト ビオスシエンセス コルポラチオン 疾患を治療するためのイミダゾロチアゾール化合物
WO2009038757A2 (en) * 2007-09-19 2009-03-26 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
CN102438588B (zh) * 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
US8865710B2 (en) * 2009-05-14 2014-10-21 Ambit Biosciences Corporation Methods of treating proliferative diseases
KR101819245B1 (ko) 2009-11-05 2018-01-16 암비트 바이오사이언시즈 코포레이션 이미다조［2,1-ｂ］［1,3］벤조티아졸 유도체의 제조 방법
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
AU2015369809B2 (en) 2014-12-22 2022-03-17 Genzyme Corporation Methods of culturing a mammalian cell
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
ES2827523T3 (es) * 2015-03-11 2021-05-21 Riken Agente terapéutico para la leucemia intratable
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2021180008A1 (zh) * 2020-03-11 2021-09-16 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US233903A (en) * 1880-11-02 Velocipede
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP4610668B2 (ja) 2006-03-17 2011-01-12 アムビト ビオスシエンセス コルポラチオン 疾患を治療するためのイミダゾロチアゾール化合物
WO2009038757A2 (en) * 2007-09-19 2009-03-26 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Also Published As

Publication number Publication date
KR101578481B1 (ko) 2015-12-17
CY1114853T1 (el) 2016-12-14
AU2008325141A1 (en) 2009-05-14
US7968543B2 (en) 2011-06-28
KR20100075853A (ko) 2010-07-05
AR069244A1 (es) 2010-01-06
JP5645667B2 (ja) 2014-12-24
SI2205244T1 (sl) 2013-12-31
KR20150105494A (ko) 2015-09-16
ES2436266T3 (es) 2013-12-30
CA2696807C (en) 2017-11-28
TW200924756A (en) 2009-06-16
DK2205244T3 (da) 2013-11-25
WO2009061446A1 (en) 2009-05-14
JP2014221765A (ja) 2014-11-27
EP2205244A1 (en) 2010-07-14
MX2010002396A (es) 2010-04-01
CA2696807A1 (en) 2009-05-14
CN101835472A (zh) 2010-09-15
PT2205244E (pt) 2013-11-26
US20090123418A1 (en) 2009-05-14
EP2596795A1 (en) 2013-05-29
JP2011503063A (ja) 2011-01-27
AU2008325141B2 (en) 2014-03-20
HRP20131083T1 (hr) 2013-12-20
EP2205244B1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
PL2205244T3 (pl) Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych
CY1122765T1 (el) Ξηρανθεισα με ψεκασμο συνθεση αc220
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
BRPI0816904B8 (pt) Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida
NI201200072A (es) Métodos y composiciones para tratar cáncer
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP1804794A4 (en) SPIROPIPERIDINE COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PT2024368E (pt) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepina-4-il]-amina como moduladores de trpv1 para o tratamento da dor
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EP2257167A4 (en) 2-AMINOIMIDAZOLE BETA-SECRETASE INHIBITORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NZ604379A (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
SI2117525T1 (sl) Uporaba 1-fenil-3-dimetilamino-propanskih spojin za terapijo nevropatske bolečine
EA201000866A1 (ru) Производные амидов 6,7-дигидро-5н-имидазо[1,2-а]имидазол-3-карбоновой кислоты
NO20084270L (no) Anvendelse av imidazo[2,1-b] -1,3,4-tiadiazol-2-sulfonamidforbindelser for behandling av nevropatisk smerte
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
CU20120081A7 (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
IL213703A (en) Compounds for the treatment of pain and other diseases
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.
EP2154138A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OF PSYCHOTIC DISORDERS, METHODS OF PREPARATION, AND USES THEREOF
IL186286A0 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
CL2007002928A1 (es) Polimorfo b de n-{2-fluoro-5-[3-(tiofen-2-carbonil)-pirazolo[1,5-a]pirimidin-7-il]-fenil}-n-metil-acetamida; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de ansiedad, epilepsia, trastornos del sueno,
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof
ZA201000987B (en) Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith